Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of linvoseltamab in high-risk MGUS and non-high-risk smoldering multiple myeloma
2023-505242-25-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, single-arm trial of linvoseltamab in monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Frequency of adverse events of special interest during safety observation period (Part 1), Frequency of treatment-emergent adverse events during safety observation period (Part 1) and 2 more. Planned start May 2024; status: authorised.
02
Drugs
linvoseltamab
03
Conditions
monoclonal gammopathy of undetermined significance (MGUS)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2023-505242-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505242-25-00.